Teleflex (NYSE:TFX) Price Target Lowered to $130.00 at Mizuho

Teleflex (NYSE:TFX - Free Report) had its price target reduced by Mizuho from $150.00 to $130.00 in a report released on Wednesday morning,Benzinga reports. Mizuho currently has a neutral rating on the medical technology company's stock.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Truist Financial dropped their target price on shares of Teleflex from $140.00 to $137.00 and set a "hold" rating for the company in a research report on Monday, May 5th. Royal Bank Of Canada set a $130.00 target price on shares of Teleflex and gave the company a "sector perform" rating in a research report on Tuesday. Wells Fargo & Company dropped their target price on shares of Teleflex from $146.00 to $137.00 and set an "equal weight" rating for the company in a research report on Friday, May 2nd. Finally, Morgan Stanley dropped their target price on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $159.63.

Teleflex Stock Performance

Shares of TFX stock traded up $0.38 during midday trading on Wednesday, hitting $113.70. 543,477 shares of the company were exchanged, compared to its average volume of 636,412. The firm has a market capitalization of $5.02 billion, a P/E ratio of 35.87, a PEG ratio of 1.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.32 and a current ratio of 2.28. The firm's 50 day moving average price is $121.24 and its two-hundred day moving average price is $142.41. Teleflex has a 52 week low of $112.32 and a 52 week high of $249.91.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.88 by $0.03. The business had revenue of $700.67 million during the quarter, compared to the consensus estimate of $699.37 million. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. Teleflex's revenue was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.21 EPS. As a group, equities research analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date was Tuesday, May 20th. Teleflex's payout ratio is 42.90%.

Institutional Investors Weigh In On Teleflex

Institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC bought a new stake in Teleflex during the 4th quarter worth approximately $29,000. Banque Cantonale Vaudoise bought a new stake in shares of Teleflex in the 1st quarter valued at $27,000. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 100 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Teleflex in the 1st quarter valued at $28,000. Finally, Brooklyn Investment Group boosted its stake in shares of Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 150 shares during the last quarter. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.